ciprofloxacin has been researched along with Liver Diseases in 15 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)." | 7.67 | Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986) |
| "Ciprofloxacin was given orally at different dose regimens: 500 mg b." | 6.66 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988) |
| "The results of this study suggest that daily ciprofloxacin may result in fewer hospitalizations for patients with advanced liver diseases awaiting liver transplantation but not by enhancing hepatic function." | 5.15 | Daily ciprofloxacin treatment for patients with advanced liver disease awaiting liver transplantation reduces hospitalizations. ( Hawkins, K; Kaita, KD; Minuk, GY; Minuk, L; Renner, E; Uhanova, J; Wong, S, 2011) |
| "The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)." | 3.67 | Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986) |
| "Ciprofloxacin was given orally at different dose regimens: 500 mg b." | 2.66 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988) |
| "Ciprofloxacin has a slightly higher extent of metabolism, while temafloxacin probably has a higher transintestinal elimination." | 2.38 | Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review. ( Kinzig, M; Mahr, G; Muth, P; Naber, KG; Sorgel, F, 1991) |
| "Complex cysts were observed by ultrasonography (in four of eight patients), computed tomography (in six of nine), and magnetic resonance imaging (in two of two)." | 2.38 | Hepatic cyst infection in autosomal dominant polycystic kidney disease. ( Brown, ML; Gross, JB; Hattery, RR; Telenti, A; Torres, VE; Van Scoy, RE, 1990) |
| "Transient fever is commonly reported as a side effect." | 1.40 | Hepatic cyst infection following aspiration sclerotherapy: a case series. ( Drenth, JP; Lantinga, MA; Wijnands, TF, 2014) |
| "Infections of these cysts do occur, but there are no reports of salmonella as the aetiologic agent." | 1.29 | Polycystic liver disease, complicated by Salmonella infection. ( Grossmann, E; Hancke, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernts, LHP | 1 |
| Wallenburg, E | 1 |
| de Jonge, HJM | 1 |
| Schaap, B | 1 |
| Kusters, R | 1 |
| Overtoom, TTC | 1 |
| Brüggemann, RJM | 1 |
| Drenth, JPH | 1 |
| Lantinga, MA | 2 |
| Buchanan, R | 1 |
| Stoesser, N | 1 |
| Crook, D | 1 |
| Bowler, IC | 1 |
| Wijnands, TF | 1 |
| Drenth, JP | 1 |
| Minuk, GY | 1 |
| Hawkins, K | 1 |
| Kaita, KD | 1 |
| Wong, S | 1 |
| Renner, E | 1 |
| Minuk, L | 1 |
| Uhanova, J | 1 |
| Toh, HS | 1 |
| Chuang, YC | 1 |
| Huang, CC | 1 |
| Lee, YL | 1 |
| Liu, YM | 1 |
| Ho, CM | 1 |
| Lu, PL | 1 |
| Liu, CE | 1 |
| Chen, YH | 1 |
| Wang, JH | 1 |
| Ko, WC | 1 |
| Yu, KW | 1 |
| Liu, YC | 1 |
| Chen, YS | 1 |
| Tang, HJ | 1 |
| Hsueh, PR | 1 |
| Casassus-Builhé, D | 1 |
| Le Bougeant, P | 1 |
| Carmois, T | 1 |
| Terrier, F | 1 |
| Chauveau, E | 1 |
| Armand, JP | 1 |
| Oddes, B | 1 |
| Styler, MJ | 1 |
| Crilley, P | 1 |
| Biggs, J | 1 |
| Moul, J | 1 |
| Copelan, E | 1 |
| Topolsky, D | 1 |
| Avalos, B | 1 |
| Penza, S | 1 |
| Sabol, P | 1 |
| Downs, K | 1 |
| Szer, J | 1 |
| Brodsky, I | 1 |
| Marks, DI | 1 |
| Grossmann, E | 1 |
| Hancke, S | 1 |
| Ghosh, SK | 1 |
| Clark, DW | 1 |
| Layton, D | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Shakir, SA | 1 |
| Sorgel, F | 1 |
| Naber, KG | 1 |
| Kinzig, M | 1 |
| Mahr, G | 1 |
| Muth, P | 1 |
| Telenti, A | 1 |
| Torres, VE | 1 |
| Gross, JB | 1 |
| Van Scoy, RE | 1 |
| Brown, ML | 1 |
| Hattery, RR | 1 |
| Fraise, AP | 1 |
| Smith, SP | 1 |
| Esposito, S | 2 |
| Galante, D | 2 |
| Barba, D | 2 |
| Bianchi, W | 1 |
| Gagliardi, R | 1 |
| Giusti, R | 1 |
| Giusti, G | 1 |
2 reviews available for ciprofloxacin and Liver Diseases
| Article | Year |
|---|---|
Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.
Topics: Aging; Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Humans; Kidney Dis | 1991 |
Hepatic cyst infection in autosomal dominant polycystic kidney disease.
Topics: Aged; Ciprofloxacin; Cysts; Enterobacter; Enterobacteriaceae Infections; Escherichia coli Infections | 1990 |
2 trials available for ciprofloxacin and Liver Diseases
| Article | Year |
|---|---|
Daily ciprofloxacin treatment for patients with advanced liver disease awaiting liver transplantation reduces hospitalizations.
Topics: Adult; Anti-Infective Agents; Bilirubin; Ciprofloxacin; Female; Hospitalization; Humans; Liver Disea | 2011 |
Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Liver Diseases | 1988 |
11 other studies available for ciprofloxacin and Liver Diseases
| Article | Year |
|---|---|
Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cysts; Humans; Liver Diseases; Polycystic Kidney, Autosomal Do | 2019 |
Multidrug-resistant Escherichia coli soft tissue infection investigated with bacterial whole genome sequencing.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; D | 2014 |
Hepatic cyst infection following aspiration sclerotherapy: a case series.
Topics: Abdominal Pain; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; C | 2014 |
Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Ente | 2012 |
[Hepatic inflammatory pseudotumor regressing with antibiotic therapy].
Topics: Aged; Biopsy; Ciprofloxacin; Clavulanic Acids; Drug Therapy, Combination; Female; Granuloma, Plasma | 2002 |
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child, | 1996 |
Polycystic liver disease, complicated by Salmonella infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cysts; Female; | 1996 |
A rare infection caused by Chryseomonas luteola.
Topics: Adult; Anti-Infective Agents; Anti-Infective Agents, Local; Chlorhexidine; Ciprofloxacin; Diabetes C | 2000 |
Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.
Topics: Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Ci | 2001 |
Ciprofloxacin in combined renal and hepatic impairment.
Topics: Bacterial Infections; Ciprofloxacin; Female; Humans; Kidney Diseases; Liver Diseases; Middle Aged | 1990 |
Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease.
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Liver Diseases; Male; Middle Aged; Resp | 1986 |